A 72-year-old man with CKD stage 3b (eGFR 38 mL/min/1.73 m²), albuminuria, and type 2 diabetes is reviewed. According to KDIGO 2024 CKD guidelines, wh...

Question

A 72-year-old man with CKD stage 3b (eGFR 38 mL/min/1.73 m²), albuminuria, and type 2 diabetes is reviewed. According to KDIGO 2024 CKD guidelines, which class of medication in addition to ACE inhibitor and SGLT2 inhibitor is recommended to further reduce progression and cardiovascular risk in appropriate patients?

Accepted Answer

Mineralocorticoid receptor antagonist (Finerenone or similar)

Answer

Non-dihydropyridine calcium channel blocker

Answer

Thiazide diuretic

Answer

Loop diuretic at high dose

Answer

Alpha-blocker

ca-mccqe1 MCQ (SBA): CKD progression risk reduction